Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 10/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3950360 | 0.85 | RXRA (0.42) | MRGPRX4IDO1TACR1RXRARXRB | |
| SCHEMBL14117328 | 0.83 | SIGMAR1 (0.40) | MRGPRX4IDO1TACR1SIGMAR1NOS1 | |
| SCHEMBL7074326 | 0.81 | IDO1 (0.40) | MRGPRX4IDO1TACR1SIGMAR1NOS1 | |
| SCHEMBL7694014 | 0.80 | TACR1 (0.43) | IDO1TACR1P2RX1 | |
| SCHEMBL140938 | 0.80 | IDO1 (0.52) | IDO1TACR1RXRARXRBRXRG | |
| SCHEMBL7078874 | 0.79 | TAAR1 (0.50) | IDO1TACR1NOS1NOS2 | |
| SCHEMBL17072154 | 0.75 | RXRA (0.37) | MRGPRX4TACR1RXRARXRBRXRG | |
| SCHEMBL11907625 | 0.75 | P2RX1 (0.42) | MRGPRX4TACR1P2RX1RXRARXRB | |
| SCHEMBL17320459 | 0.74 | MGLL (0.42) | MRGPRX4IDO1TACR1 | |
| SCHEMBL14092975 | 0.72 | GABRA1 (0.39) | IDO1TACR1P2RX1RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049517-B1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2013-11-27 | — | — | EP | disclosed |
| CN-101490035-B | Amino-piperidine derivatives as CETP inhibitors | NOVARTIS AG | 2013-02-13 | — | — | CN | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286790-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| CN-101490035-A | Amino-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-07-22 | — | — | CN | disclosed |
| EP-2049517-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009435-A1 | AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286790-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | MRGPRX4 579/4885IDO1 4220/4885TACR1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.